Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices | Videos
Production & Manufacturing
OTC
Return to: PBR Home | Production & Manufacturing | OTC

Catalent to acquire OTC softgel maker Accucaps Industries

PBR Staff Writer Published 29 November 2016

US based Catalent has agreed to acquire Accucaps Industries, a Canadian pharmaceutical contract development and manufacturing organization specializing in the soft gelatin dose form.

Accucaps develops and manufactures over-the-counter (OTC), high potency and conventional pharmaceutical softgels.

The companies did not disclose the financial details of the transaction, which is subject to approval from the Canadian government authorities.

The acquisition will expand Catalent’s worldwide softgel capabilities with the addition of a portfolio of OTC and prescription products supplied to the North American market.

As part of the deal, more than 500 employees, at Accucaps' two facilities in Windsor and Strathroy, Ontario, will join Catalent’s global network of 11 softgel technologies facilities.

Catalent softgel technologies president Aris Gennadios said: “Significant investments already made by Accucaps align well with Catalent’s own strategic goals, to offer our customers access to more products, capacity, and integrated solutions for differentiated products and better treatments.”

The two facilities undertake blistering, bottling and other packaging activities for Accucaps in addition to development and manufacturing of softgel.

Catalent has over 30 facilities spread across five continents to develop drugs, biologics and consumer health products.

In late October, Catalent broke ground on a new extension to its Madison, Wisconsin biologics manufacturing facility.

Catalent’s other acquisitions in recent times include US drug development and clinical manufacturing company Pharmatek, also for an undisclosed sum.

With Pharmatek acquisition, Catalent intends to enhance its drug development services and dry spraying technology.